1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Liver Transplant Rejection - Drugs In Development, 2022, provides an overview of the Liver Transplant Rejection (Immunology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Liver transplantation is the conventional therapy used in various liver diseases. Liver has the unique ability to regenerate or grow, unlike any other organ in the body. Liver transplant replaces an injured or diseased liver with a healthy one. An entire liver or just a section may be transplanted. Following a transplant, the immune system may consider the transplanted liver as foreign and may work against it. Patients may hence develop complications and ultimately reject the new organ. Therefore, immunosuppressive drugs are administered simultaneously. These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Liver Transplant Rejection - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Liver Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Liver Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Liver Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase 0, Preclinical, Discovery and Unknown stages are 1, 5, 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 1, 2, 1 and 2 molecules, respectively.
Liver Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Transplant Rejection (Immunology).
- The pipeline guide reviews pipeline therapeutics for Liver Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Liver Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Liver Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Liver Transplant Rejection (Immunology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Liver Transplant Rejection (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Liver Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Liver Transplant Rejection - Overview
- Liver Transplant Rejection - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Liver Transplant Rejection - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Liver Transplant Rejection - Companies Involved in Therapeutics Development
- Alexion Pharmaceuticals Inc
- Astellas Pharma Inc
- Dompe Farmaceutici SpA
- Genexine Inc
- ITB-Med AB
- Junten Bio Co Ltd
- Novartis AG
- Pharmapraxis
- Quell Therapeutics Ltd
- Veloxis Pharmaceuticals AS
- Liver Transplant Rejection - Drug Profiles
- Cellular Immunotherapy for Liver Transplant Rejection - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Cellular Immunotherapy for Liver Transplantation - Drug Profile
- Product Description
- Mechanism Of Action
- Cellular Immunotherapy for Liver Transplantation - Drug Profile
- Product Description
- Mechanism Of Action
- eculizumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Gene Therapy for High-Grade Glioma and Liver Transplantation - Drug Profile
- Product Description
- Mechanism Of Action
- GXP-10 - Drug Profile
- Product Description
- Mechanism Of Action
- iscalimab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- JB-101 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- JB-102 - Drug Profile
- Product Description
- Mechanism Of Action
- QEL-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- reparixin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- rituximab biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- siplizumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules for Liver Transplant Rejection and Kidney Transplant Rejection - Drug Profile
- Product Description
- Mechanism Of Action
- tacrolimus - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- tacrolimus ER - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TR-002 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Liver Transplant Rejection - Dormant Projects
- Liver Transplant Rejection - Discontinued Products
- Liver Transplant Rejection - Product Development Milestones
- Featured News & Press Releases
- Jul 16, 2021: FDA approves new use of transplant drug based on real-world evidence
- Jan 17, 2020: Astellas announces construction of new manufacturing facility for Active Pharmaceutical Ingredient of Prograf in Toyama Technology Center
- Mar 18, 2019: Astellas launches PROGRAF Granules (tacrolimus for oral suspension) in the U.S. for Pediatric Liver, Heart, and Kidney Transplant Patients
- Dec 04, 2009: Hikma signs new agreement for Advagraf with Astellas
- Jun 23, 2008: Astellas submit an sNDA for the immunosuppressant Prograf for Ulcerative Colitis in Japan
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Liver Transplant Rejection, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Liver Transplant Rejection - Pipeline by Alexion Pharmaceuticals Inc, 2022
- Liver Transplant Rejection - Pipeline by Astellas Pharma Inc, 2022
- Liver Transplant Rejection - Pipeline by Dompe Farmaceutici SpA, 2022
- Liver Transplant Rejection - Pipeline by Genexine Inc, 2022
- Liver Transplant Rejection - Pipeline by ITB-Med AB, 2022
- Liver Transplant Rejection - Pipeline by Junten Bio Co Ltd, 2022
- Liver Transplant Rejection - Pipeline by Novartis AG, 2022
- Liver Transplant Rejection - Pipeline by Pharmapraxis, 2022
- Liver Transplant Rejection - Pipeline by Quell Therapeutics Ltd, 2022
- Liver Transplant Rejection - Pipeline by Veloxis Pharmaceuticals AS, 2022
- Liver Transplant Rejection - Dormant Projects, 2022
- Liver Transplant Rejection - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Liver Transplant Rejection, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alexion Pharmaceuticals Inc
- Astellas Pharma Inc
- Dompe Farmaceutici SpA
- Genexine Inc
- ITB-Med AB
- Junten Bio Co Ltd
- Novartis AG
- Pharmapraxis
- Quell Therapeutics Ltd
- Veloxis Pharmaceuticals AS
